Tg Therapeutics (TGTX) Equity Average: 2016-2025
Historic Equity Average for Tg Therapeutics (TGTX) over the last 10 years, with Sep 2025 value amounting to $441.8 million.
- Tg Therapeutics' Equity Average rose 139.00% to $441.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $441.8 million, marking a year-over-year increase of 139.00%. This contributed to the annual value of $191.4 million for FY2024, which is 74.75% up from last year.
- According to the latest figures from Q3 2025, Tg Therapeutics' Equity Average is $441.8 million, which was up 72.01% from $256.9 million recorded in Q2 2025.
- Over the past 5 years, Tg Therapeutics' Equity Average peaked at $482.3 million during Q1 2021, and registered a low of $33.9 million during Q2 2023.
- Over the past 3 years, Tg Therapeutics' median Equity Average value was $168.8 million (recorded in 2024), while the average stood at $181.1 million.
- In the last 5 years, Tg Therapeutics' Equity Average skyrocketed by 2,488.79% in 2021 and then plummeted by 78.89% in 2023.
- Over the past 5 years, Tg Therapeutics' Equity Average (Quarterly) stood at $274.3 million in 2021, then tumbled by 71.01% to $79.5 million in 2022, then spiked by 104.49% to $162.6 million in 2023, then rose by 27.44% to $207.3 million in 2024, then surged by 139.00% to $441.8 million in 2025.
- Its last three reported values are $441.8 million in Q3 2025, $256.9 million for Q2 2025, and $229.8 million during Q1 2025.